An observational study in HIV Infections, sponsored by University of Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-17.
Sponsored by University of Zurich · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in HIV Infections with a site in Switzerland — 4 open to participants now, 6 under way, 3 of them phase 3. HIV Infections · Switzerland.
Among the 81 studies in HIV Infections with a site in Switzerland, this one is the 5th largest by planned enrollment of the 17 observational ones that give a count, is one of 2 that started in 2002, is one of 17 observational ones, and was the 30th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →4 of the 81 studies in HIV Infections with a site in Switzerland are open now. Recruiting first, the newest first:
Gilead Sciences · Sites in Switzerland, United States, Australia and 5 more countries
Ages 18+
University of Zurich · Sites in Switzerland
Ages 18+
Centre Hospitalier Universitaire Vaudois · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 14 · Phase 3 32 · Phase 4 10
First in 1999; this study’s year is marked. 2 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 200 across 781 observational studies indexed under HIV Infections.
Median enrollment 438 across the 61 interventional studies, 249 across the 17 observational. Of the 68 that completed or were terminated, 28 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 81 have an industry lead sponsor. The 10 most frequent:
University of Zurich is the lead sponsor of 1,051 studies on the registry; 134 are open to participants now.
University of Zurich has 5 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 81 studies in HIV Infections with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Aim of the study: To study and to describe factors which could influence the course of primary HIV infection (PHI) and factors that in turn could be influenced through PHI.
In summary, this study will provide comprehensive knowledge on early HIV-infection with regard to epidemiology, impact of early-cART on the course of disease and forms the base for a variety of translational research projects addressing early key pathogenesis events between virus and host, relevant for the course of disease, for transmission, for development of vaccines and new treatment strategies.
The ZPHI is a longitudinal, observational, multi-center study. The ZPHI study started in 2002: The first patient visit (FPFV) was in January 2002. Since then, we continuously enrolled patients fulfilling the inclusion criteria. Because the ZPHI is an observational, longitudinal study and the HIV epidemic in Switzerland evolves continuously a clear study end point is not possible. We plan to critically revise the current protocol every 5 years and at that point, also evaluate whether the study should be continued.
This study so far has been highly successful in the recruitment of patients with a PHI. To date we have enrolled more than 480 patients with a documented PHI since project start in 2002.
Men and women > 18 years with a documented acute or recent HIV-1 infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A) acute -1 infection, defined as:
B) recent HIV-1 infection, defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patients with primary HIV-1 infection will receive combination antiretroviral therapy with standard drugs approved by Swiss Medic.
Evaluation of early events between virus and host to better understand HIV-pathogenesis during the early course of HIV infection.
The enrolment and the longitudinal follow up of patients with a documented PHI will allow us to study early events between virus and host and to better understand HIV-pathogenesis during the early course of HIV infection. We aim to expand the established biobank in order to collect samples from patients with an acute or recent HIV infection: For the biobank, we will collect blood samples which are obtained in addition to the routinely collected clinical samples. This concerns ETDA blood samples, initially collected every 3 months until week 48, followed by every six months until week 240 and thereafter once yearly from week 240 onwards. Moreover, a stool sample will be collected and stored for research purposes only. In addition, we will store routinely collected CSF, STI swabs (rectal, virginal, urethral, pharyngeal), urethral swabs, stool samples and in case of high-resolution anoscopy also rectal biopsy materialin the biobanks of the accoding institutes.
Time frame: 30 years
Systematic Collection and Analysis of Personal Health and Clinical Data
* Secondary Outcome: Number of participants with complete health and clinical datasets analyzed. * Unit of Measure: Count of datasets.
Time frame: 30 Years
Systematic Assessment of PHI to Identify Atypical Presentations
* Secondary Outcome: Percentage of participants presenting atypical symptoms of PHI. * Unit of Measure: Percentage.
Time frame: 30 Years
Systematic Screening for Sexually Transmitted Infections (STIs)
* Secondary Outcome: Number of STI cases identified, classified by clinical characteristics and resistance patterns. * Unit of Measure: Count of cases
Time frame: 30 Years
Identification of Transmission Networks for HIV and Acute Hepatitis C
* Secondary Outcome: Number of transmission clusters identified through phylogenetic analysis. * Unit of Measure: Count of clusters.
Time frame: 30 Years
Investigation of Viral Factors in HIV-1 Pathogenesis
* Secondary Outcome: Percentage of patient samples with drug-resistant variants, viral diversity, or replication capacity metrics. * Unit of Measure: Percentage or specific diversity/replication scores.
Time frame: 30 Years
Analysis of Biological Characteristics of Transmitted Viruses
* Secondary Outcome: Replication capacity of transmitted viruses * Unit of Measure: Replication cycles/hour
Time frame: 30 Years
Study of HIV-Specific Immune Responses and Innate Immune System Factors
* Secondary Outcome: Concentration of immune markers, such as cytokine levels, associated with specific immune responses. * Unit of Measure: Concentration (pg/mL).
Time frame: 30 Years
Genetic Studies Using Next-Generation Sequencing to Investigate Traits Linked to HIV Progression
* Secondary Outcome: Number of genetic polymorphisms associated with differential progression in natural HIV infection. * Unit of Measure: Count of identified polymorphisms.
Time frame: 30 Years
Plan to share: No
The record gives a start of Jan 2002, a primary completion of Dec 2028 and a completion of Dec 2028. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.